Fulcrum Therapeutics (FULC) Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Current Assets data on file, last reported at $338.7 million in Q1 2026.

• On a quarterly basis, Current Assets rose 45.63% year-over-year to $338.7 million in Q1 2026; TTM through Mar 2026 was $338.7 million, a 45.63% increase from a year earlier, with the FY2025 full-year figure at $357.5 million, up 43.04% from the prior year.
• Current Assets for Q1 2026 stood at $338.7 million, down from $357.5 million in the prior quarter.
• Over the last five years, Current Assets for FULC reached as high as $357.5 million in Q4 2025 and fell as low as $174.2 million in Q2 2022.
• Historically, Current Assets has averaged $251.2 million across 5 years, with a median of $242.2 million in 2023.
• Across the five-year window, Current Assets surged 62.38% in 2023 and declined 28.03% in 2024, its largest moves.
• Year by year, Current Assets stood at $207.5 million in 2022, then increased by 16.71% to $242.2 million in 2023, then advanced by 3.19% to $249.9 million in 2024, then jumped by 43.04% to $357.5 million in 2025, then dropped by 5.26% to $338.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $338.7 million in Q1 2026, $357.5 million in Q4 2025, and $205.9 million in Q3 2025.